Wendy Short Bartie, executive vice president, Corporate Affairs, is responsible for advancing our company strategy through strategic communications, corporate social responsibility, corporate marketing and brand reputation, and patient advocacy. Wendy also oversees the Bristol Myers Squibb Foundation, an independent organization that works to advance the health of underserved populations globally. Wendy also serves as the executive sponsor of the Bristol Myers Squibb PRIDE Alliance.
Wendy brings a blend of business acumen and purpose-driven leadership to this role. With degrees in both communications and law, she built her industry experience with multiple roles in Commercialization and most recently led our oncology portfolio, where she was responsible for delivering cutting-edge cancer-fighting therapies to patients around the world. She previously served as the SVP and general manager of multiple divisions within Bristol Myers Squibb, and served as chief of staff to former CEO, Giovanni Caforio.
“In Corporate Affairs, we don’t just tell our story, we shape it. We ensure that the company’s reputation, value and impact are clearly articulated and deeply understood by the stakeholders that matter most,” says Wendy. “I am proud to lead a team that is uniquely equipped to partner with and empower every function across the enterprise so that we’re delivering on our patient-centered mission.”
In 2024, Wendy was honored with the WOCIP Illuminator Award and was named one of Savoy Magazine’s Most Influential Executives in Corporate America. She has also previously been recognized by HBA as a Luminary in 2020 and was named an HBA Rising Star in 2015.
Wendy serves as a board member for both the Healthcare Businesswomen’s Association and BioNJ. She is a trustee of Newark Academy and a member of The Links, Incorporated, and Jack and Jill of America. She is also a member of the Executive Leadership Council.
Wendy received her bachelor of arts from Clark Atlanta University and her juris doctor from Loyola University Chicago, School of Law.
What is Wendy Wendy Short Bartie's net worth?
The estimated net worth of Wendy Wendy Short Bartie is at least $263.54 thousand as of August 2nd, 2025. Ms. Short Bartie owns 5,066 shares of Bristol Myers Squibb stock worth more than $263,538 as of December 4th. This net worth evaluation does not reflect any other assets that Ms. Short Bartie may own. Learn More about Wendy Wendy Short Bartie's net worth.
How do I contact Wendy Wendy Short Bartie?
Has Wendy Wendy Short Bartie been buying or selling shares of Bristol Myers Squibb?
Wendy Wendy Short Bartie has not been actively trading shares of Bristol Myers Squibb over the course of the past ninety days. Most recently, Bartie Wendy Short sold 378 shares of the business's stock in a transaction on Saturday, August 2nd. The shares were sold at an average price of $44.23, for a transaction totalling $16,718.94. Following the completion of the sale, the executive vice president now directly owns 5,066 shares of the company's stock, valued at $224,069.18. Learn More on Wendy Wendy Short Bartie's trading history.
Who are Bristol Myers Squibb's active insiders?
Bristol Myers Squibb's insider roster includes Mark Alles (CEO), Christopher Boerner (EVP), Giovanni Caforio (CEO), Adam Dubow (SVP), Joseph Eid (SVP), John Elicker (EVP), David Elkins (CFO), Benjamin Hickey (President, RayzeBio), Samit Hirawat (EVP, Chief Medical Officer and Head of Development), Sandra Leung (EVP), Dinesh Paliwal (Director), Robert Plenge (EVP), Ann Powell (EVP), Theodore Samuels, II (Director), Karen Santiago (SVP), Louis Schmukler (EVP), Wendy Short Bartie (Executive Vice President, Corporate Affairs), Rupert Vessey (EVP), and Paul von Autenried (EVP). Learn More on Bristol Myers Squibb's active insiders.
Are insiders buying or selling shares of Bristol Myers Squibb?
During the last year, Bristol Myers Squibb insiders bought shares 2 times. They purchased a total of 6,073 shares worth more than $302,188.32. During the last year, insiders at the biopharmaceutical company sold shares 3 times. They sold a total of 56,475 shares worth more than $2,670,885.91. The most recent insider tranaction occured on September, 2nd when EVP David V Elkins sold 56,000 shares worth more than $2,650,480.00. Insiders at Bristol Myers Squibb own 0.1% of the company.
Learn More about insider trades at Bristol Myers Squibb. Information on this page was last updated on 9/2/2025.
